Loading...
Please wait, while we are loading the content...
Similar Documents
Clinical determinants of long-term survival in metastatic uveal melanoma.
| Content Provider | Europe PMC |
|---|---|
| Author | Koch, Elias A. T. Petzold, Anne Wessely, Anja Dippel, Edgar Erdmann, Michael Heinzerling, Lucie Hohberger, Bettina Knorr, Harald Leiter, Ulrike Meier, Friedegund Mohr, Peter Rahimi, Farnaz Schell, Beatrice Schlaak, Max Terheyden, Patrick Schuler-Thurner, Beatrice Ugurel, Selma Utikal, Jochen Vera, Julio Weichenthal, Michael Ziller, Fabian Berking, Carola Heppt, Markus V. |
| Abstract | This study aimed to identify prognostic factors in patients with metastatic uveal melanoma (UM) that were associated with long-term survival in a real-world setting. A total of 94 patients with metastatic UM were included from German skin cancer centers and the German national skin cancer registry (ADOReg). Data were analyzed for the response to treatment, progression-free survival, and overall survival (OS). Prognostic factors were explored with univariate Cox regression, log-rank, and χ2-tests. Identified factors were subsequently validated after the population was divided into two cohorts of short-term survival (< 2 years OS, cohort A, n = 50) and long-term survival (> 2 years OS, cohort B, n = 44). A poor ECOG performance status (hazard ratio [HR] 2.0, 95% confidence interval [CI] 1.0–3.9) and elevated serum LDH (HR 2.0, 95% CI 1.0–3.8) were associated with a poor OS, whereas a good response to immune checkpoint blockade (ICB, p < 0.001), radiation therapy (p < 0.001), or liver-directed treatments (p = 0.01) were associated with a prolonged OS. Long-term survivors (cohort B) showed a higher median number of organs affected by metastasis (p < 0.001), while patients with liver metastases only were more common in cohort A (40% vs. 9%; p = 0.002). A partial response to ICB was observed in 16% (12/73), being 21% (8/38) for combined ICB, 17% (1/6) for single CTLA4 inhibition, and 10% (3/29) for single PD1 inhibition. One complete response occurred in cohort B with combined ICB. We conclude that the response to ICB and the presence of extrahepatic disease were favorable prognostic factors for long-term survival.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00262-021-03090-4. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9123041&blobtype=pdf |
| ISSN | 03407004 |
| Journal | Cancer Immunology, Immunotherapy [Cancer Immunol Immunother] |
| Volume Number | 71 |
| DOI | 10.1007/s00262-021-03090-4 |
| PubMed Central reference number | PMC9123041 |
| Issue Number | 6 |
| PubMed reference number | 34709438 |
| e-ISSN | 14320851 |
| Language | English |
| Publisher | Springer Berlin Heidelberg |
| Publisher Date | 2021-10-28 |
| Publisher Place | Berlin/Heidelberg |
| Access Restriction | Open |
| Rights License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2021 |
| Subject Keyword | Uveal melanoma Immune checkpoint blockade Liver metastases Liver-directed treatment Long-term survival Registry |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology and Allergy Cancer Research Immunology Oncology |
